<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl1">
 <label>Table 1</label>
 <caption>
  <p>Shortlisted drugs by SP-docking for targeting M
   <sup>pro</sup> of SARS-CoV-2
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="2">S. No</th>
    <th rowspan="2">Name of molecule</th>
    <th rowspan="2">Current therapeutic indications</th>
    <th rowspan="2">Docking score</th>
    <th colspan="2">Molecular interactions
     <hr/>
    </th>
   </tr>
   <tr>
    <th>H-bond-forming interactions</th>
    <th>π-π stacking or π-cation interaction</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>1</td>
    <td>Aprepitant</td>
    <td>Chemotherapy-induced emesis, Postoperative nausea and vomiting</td>
    <td align="char">−6.892</td>
    <td>-</td>
    <td>HIE41</td>
   </tr>
   <tr>
    <td>2</td>
    <td>Barnidipine</td>
    <td>Hypertension</td>
    <td align="char">−6.421</td>
    <td>ASN142, CYS145, GLU166(2)</td>
    <td>HIE41</td>
   </tr>
   <tr>
    <td>3</td>
    <td>Tipiracil</td>
    <td>Bioavailability enhancer of Triflurudine in Colorectal cancer</td>
    <td align="char">−6.331</td>
    <td>HIS164, HIS166</td>
    <td>HIE41</td>
   </tr>
   <tr>
    <td>4</td>
    <td>Arbutin</td>
    <td>Skin-lightening agent, Hyperpigmentation</td>
    <td align="char">−6.206</td>
    <td>ASN142(2)</td>
    <td>HIE41</td>
   </tr>
   <tr>
    <td>5</td>
    <td>Terbutaline</td>
    <td>Asthma, Wheezing, COPD</td>
    <td align="char">−5.846</td>
    <td>GLY143, HIS164, GLN189</td>
    <td>HIE41</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Residues ASN: Aspargine; CYS: Cysteine; GLU: Glutamic acid; HIS: Histidine; GLY: Glycine; GLN: Glutamine; HIE: Histidine (HISέ).</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
